Why the study?
To investigate whether fenofibrate as an add-on to statin treatment reduces persistent cardiovascular risk in adults with metabolic syndrome in a real-world setting.
Does fenofibrate added to statin treatment reduce composite cardiovascular events in adults with metabolic syndrome?
Population
29 771 adults (≥40 years) with metabolic syndrome receiving statin treatment in Korea
Comparison
Combined treatment (statin plus fenofibrate) vs statin only treatment
Design
Population-based propensity matched cohort study
Authors
Loading...
May support fenofibrate add-on in statin-treated metabolic syndrome; hypothesis-generating and requires randomized confirmation before practice change.
Does fenofibrate added to statin treatment reduce composite cardiovascular events in adults with metabolic syndrome?
Fenofibrate added to statin therapy significantly reduces the risk of major cardiovascular events in adults with metabolic syndrome compared to statin therapy alone.
Kim et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: